Pacific Biosciences of California, Inc.PACBNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank51
5Y CAGR-52.2%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-52.2%/yr
Long-term compound
Percentile
P51
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 0.14% |
| Q3 2025 | 1.41% |
| Q2 2025 | -22.46% |
| Q1 2025 | 5.78% |
| Q4 2024 | 7.64% |
| Q3 2024 | -33.70% |
| Q2 2024 | -11.44% |
| Q1 2024 | -2.44% |
| Q4 2023 | -6.25% |
| Q3 2023 | 2.90% |
| Q2 2023 | -5.65% |
| Q1 2023 | 14.82% |
| Q4 2022 | -9.49% |
| Q3 2022 | -6.47% |
| Q2 2022 | -4.89% |
| Q1 2022 | 24.34% |
| Q4 2021 | 54.78% |
| Q3 2021 | 23.54% |
| Q2 2021 | 8.36% |
| Q1 2021 | 17.92% |
| Q4 2020 | 5.82% |
| Q3 2020 | 9.71% |
| Q2 2020 | -1.57% |
| Q1 2020 | 6.85% |
| Q4 2019 | -4.60% |
| Q3 2019 | 0.35% |
| Q2 2019 | -3.71% |
| Q1 2019 | -4.78% |
| Q4 2018 | 13.28% |
| Q3 2018 | -8.35% |
| Q2 2018 | -3.97% |
| Q1 2018 | 4.38% |
| Q4 2017 | -1.38% |
| Q3 2017 | -6.15% |
| Q2 2017 | -0.52% |
| Q1 2017 | 4.40% |
| Q4 2016 | -7.00% |
| Q3 2016 | -0.25% |
| Q2 2016 | 7.10% |
| Q1 2016 | 10.91% |